Becton, Dickinson and Company (BDX) , popularly known as BD, recently received the FDA's approval for the use of self-collected vaginal specimens for human papillomavirus (HPV) testing when cervical specimens cannot otherwise be obtained. The approval is expected to enable women to self-collect vaginal specimens for HPV testing in a healthcare setting, including non-traditional locations such as retail pharmacies or mobile clinics. Per estimates, HPV is the cause of virtually all cervical cancer and HPV tes ...

FRANKLIN LAKES, N.J., May 15, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced U.S. Food and Drug Administration (FDA) approval for the use of self-collected vaginal specimens for human papillomavirus (HPV) testing when cervical specimens cannot otherwise be obtained. The approval allows women to self-collect vaginal specimens for HPV testing in a health care setting, which could include non-traditional locations such as a reta ...

Part I. FINANCIAL INFORMATION [Item 1. Financial Statements (Unaudited)](index=3&type=section&id=Item%201.%20Financial%20Statements%20(Unaudited)) BD's unaudited Q2 FY2024 financials show revenue growth, mixed net income, increased assets/liabilities, and improved operating cash flow [Condensed Consolidated Statements of Income](index=3&type=section&id=Condensed%20Consolidated%20Statements%20of%20Income) Q2 & Six Months FY2024 vs FY2023 Income Statement Highlights (in millions, except per share data) | Metric | Three Months Ended Mar 31, 2024 | Three Months Ended Mar 31, 2023 | Six Months Ended Mar 31, 2024 | Six Months Ended Mar 31, 2023 | | :--- | :--- | :--- | :--- | :--- | | **Revenues** | $5,045 | $4,821 | $9,751 | $9,407 | | **Operating Income** | $734 | $628 | $1,173 | $1,213 | | **Net Income** | $537 | $460 | $818 | $969 | | **Diluted EPS** | $1.85 | $1.53 | $2.81 | $3.24 | [Condensed Consolidated Statements of Comprehensive Income](index=4&type=section&id=Condensed%20Consolidated%20Statements%20of%20Comprehensive%20Income) - Comprehensive income for Q2 FY2024 was **$516 million**, up from **$445 million** in Q2 FY2023; six-month comprehensive income decreased to **$831 million** from **$882 million** due to higher net foreign currency translation losses[4](index=4&type=chunk) [Condensed Consolidated Balance Sheets](index=5&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Balance Sheet Summary (in millions) | Account | March 31, 2024 | September 30, 2023 | | :--- | :--- | :--- | | **Total Current Assets** | $10,340 | $8,676 | | **Total Assets** | $54,157 | $52,780 | | **Total Current Liabilities** | $7,327 | $6,641 | | **Long-Term Debt** | $15,995 | $14,738 | | **Total Liabilities** | $28,510 | $26,984 | | **Total Shareholders' Equity** | $25,647 | $25,796 | [Condensed Consolidated Statements of Cash Flows](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Six Months Ended March 31 Cash Flow Summary (in millions) | Activity | 2024 | 2023 | | :--- | :--- | :--- | | **Net Cash Provided by Operating Activities** | $1,369 | $584 | | **Net Cash Used for Investing Activities** | $(1,289) | $(524) | | **Net Cash Provided by Financing Activities** | $843 | $835 | | **Net increase in cash** | $913 | $909 | [Notes to Condensed Consolidated Financial Statements](index=7&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) The notes detail accounting changes, shareholder equity, legal contingencies, revenue disaggregation, segment performance, and debt and derivative instruments - The company adopted a new accounting standard on October 1, 2023, requiring additional disclosures regarding supplier finance programs[7](index=7&type=chunk) - In Q1 FY2024, the company repurchased **2.118 million shares** of common stock for **$500 million** under an accelerated share repurchase agreement[83](index=83&type=chunk) - Product liability and legal defense cost accruals amounted to approximately **$1.7 billion** as of March 31, 2024, a decrease from **$1.9 billion** at September 30, 2023, mainly due to settlement payments[41](index=41&type=chunk) - The company has unsatisfied performance obligations of approximately **$2.3 billion** for service contracts and pending installations, and an additional **$2.1 billion** for minimum purchase commitments, expected to be recognized over the next three years and customer relationship periods, respectively[45](index=45&type=chunk)[95](index=95&type=chunk) - In February 2024, the company issued **$625 million** of 4.874% notes, **$550 million** of 5.110% notes, and **€750 million** of 3.519% notes[110](index=110&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=21&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management attributes Q2 FY2024 revenue growth to strong segment performance, improved operating cash flow, and ongoing strategic execution amidst regulatory and macroeconomic challenges [Results of Operations](index=22&type=section&id=Results%20of%20Operations) Q2 FY2024 worldwide revenues increased 4.6% to $5.045 billion, driven by volume growth across all segments, while gross profit margin slightly decreased Q2 FY2024 Revenue Growth Drivers | Driver | % Contribution to Revenue Growth | | :--- | :--- | | Volume/other | 5.0% | | Impact due to sale of Surgical Instrumentation platform | (0.9)% | | Pricing | 0.6% | | Foreign currency translation | (0.1)% | | **Total Increase in Revenues** | **4.6%** | Q2 FY2024 Revenue by Segment (in millions) | Segment | Q2 2024 Revenue | Q2 2023 Revenue | Total Change | FXN Change | | :--- | :--- | :--- | :--- | :--- | | BD Medical | $2,449 | $2,360 | 3.8% | 3.7% | | BD Life Sciences | $1,304 | $1,275 | 2.2% | 2.3% | | BD Interventional | $1,292 | $1,186 | 9.0% | 9.5% | | **Total Revenues** | **$5,045** | **$4,821** | **4.6%** | **4.7%** | - U.S. revenue grew **6.3%** in Q2, while International revenue grew **2.4%** (**2.6% FXN**); emerging markets revenue grew **2.6%** (**3.2% FXN**), driven by South Asia, EMA, and Latin America, partially offset by unfavorable market dynamics in China[151](index=151&type=chunk)[231](index=231&type=chunk)[262](index=262&type=chunk) [Liquidity and Capital Resources](index=29&type=section&id=Liquidity%20and%20Capital%20Resources) The company's liquidity strengthened with increased cash from operations, a $2.75 billion undrawn credit facility, and total debt of $18.0 billion - Net cash provided by operating activities for the six months ended March 31, 2024, was **$1.369 billion**, compared to **$584 million** for the same period in 2023[126](index=126&type=chunk)[270](index=270&type=chunk) - During the first six months of FY2024, the company paid **$550 million** in dividends and repurchased **$500 million** of common stock[127](index=127&type=chunk)[255](index=255&type=chunk) - The company has a **$2.75 billion** senior unsecured revolving credit facility expiring in September 2026, with no borrowings outstanding as of March 31, 2024[129](index=129&type=chunk) [Regulatory Matters](index=31&type=section&id=Regulatory%20Matters) The company is addressing new EPA regulations for ethylene oxide emissions and operating its Alaris infusion pump business under an FDA Consent Decree - The EPA's final NESHAP regulation for Ethylene Oxide Emissions became effective on April 5, 2024, with a two-year compliance deadline, and the company is reviewing its operational impact[275](index=275&type=chunk) - The BD Alaris infusion pump unit is operating under an FDA Consent Decree, with the company having received 510(k) clearance for its updated system in July 2023 and actively remediating or replacing devices in the U.S. market[276](index=276&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=36&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) No material changes in market risk disclosures have occurred since the fiscal year ended September 30, 2023 - There have been no material changes in market risk disclosures since the fiscal year ended September 30, 2023[247](index=247&type=chunk) [Controls and Procedures](index=36&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that the company's disclosure controls and procedures were effective as of March 31, 2024, with no material changes to internal control over financial reporting - Based on an evaluation as of March 31, 2024, the CEO and CFO concluded that the company's disclosure controls and procedures were effective[279](index=279&type=chunk) Part II. OTHER INFORMATION [Legal Proceedings](index=37&type=section&id=Item%201.%20Legal%20Proceedings) The company is involved in various legal proceedings, with detailed information incorporated by reference from Note 5 of the financial statements - Information regarding legal proceedings is incorporated by reference from Note 5 of the Notes to Condensed Consolidated Financial Statements[166](index=166&type=chunk) [Risk Factors](index=38&type=section&id=Item%201A.%20Risk%20Factors) No material changes to the risk factors previously disclosed in the company's 2023 Annual Report on Form 10-K were reported - No material changes to risk factors were reported compared to the 2023 Annual Report[136](index=136&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=38&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) During Q1 FY2024, the company purchased 1,532 shares of common stock, with 6,681,777 shares remaining available for repurchase Issuer Purchases of Equity Securities (For the three months ended March 31, 2024) | Period | Total Number of Shares Purchased | Average Price Paid per Share | | :--- | :--- | :--- | | January 1 - 31, 2024 | 1,280 | $238.11 | | February 1 – 29, 2024 | 252 | $239.08 | | March 1 – 31, 2024 | 0 | N/A | | **Total** | **1,532** | **$238.27** | - As of March 31, 2024, **6,681,777 shares** may yet be purchased under the existing repurchase program[167](index=167&type=chunk)[281](index=281&type=chunk) [Other Information](index=39&type=section&id=Item%205.%20Other%20Information) An executive vice president adopted a Rule 10b5-1 trading plan for the potential sale of up to 6,600 shares of common stock, terminating by June 1, 2025 - On February 12, 2024, Roland Goette, EVP and President EMEA, adopted a Rule 10b5-1 trading plan for the sale of up to **6,600 shares** of BD common stock[283](index=283&type=chunk)

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium includes access to the Zacks Style Scores as we ...

Becton, Dickinson and Company (NYSE:BDX) Q2 2024 Earnings Conference Call May 2, 2024 8:00 AM ET Company Participants Greg Rodetis - Senior Vice President, Treasurer, and Head of Investor Relations Tom Polen - Chairman, Chief Executive Officer, and President Chris DelOrefice - Executive Vice President, and Chief Financial Officer Mike Garrison - President of the Medical Segment Dave Hickey - President of the Life Sciences Segment Rick Byrd - President of the Interventional Segment Conference Call Participan ...

For the quarter ended March 2024, Becton Dickinson (BDX) reported revenue of $5.05 billion, up 4.7% over the same period last year. EPS came in at $3.17, compared to $2.86 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $5.03 billion, representing a surprise of +0.30%. The company delivered an EPS surprise of +7.09%, with the consensus EPS estimate being $2.96.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street ...

Becton, Dickinson and Company (BDX) , popularly known as BD, delivered adjusted earnings per share (EPS) of $3.17 in the second quarter of fiscal 2024, up 10.8% year over year. The figure topped the Zacks Consensus Estimate by 7.1%.The adjustments include expenses related to purchase accounting adjustments and integration costs, among others.GAAP EPS for the quarter was $1.85, reflecting an improvement of 20.9% from the year-earlier figure.Revenues in DetailBD registered revenues of $5.05 billion in the fis ...

Becton Dickinson (BDX) came out with quarterly earnings of $3.17 per share, beating the Zacks Consensus Estimate of $2.96 per share. This compares to earnings of $2.86 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 7.09%. A quarter ago, it was expected that this medical device manufacturer would post earnings of $2.39 per share when it actually produced earnings of $2.68, delivering a surprise of 12.13%.Over the last four qua ...

| --- | --- | --- | --- | |---------------------|-----------------------|----------------------------------|-------| | | | | | | | | | | | | | | | | Q2 FY24 May 2, 2024 | Earnings Presentation | | | | | | | | | | | Advancing the world of health ™ | | Caution Concerning Forward-Looking Statements This presentation and accompanying audio webcast contain estimates and other forward-looking statements (as defined under federal securities laws) reqarding BD's futue pro performance, including, but not limited to, ...

BD Reports Second Quarter Fiscal 2024 Financial Results • Q2 revenue of $5.0 billion increased 4.6% as reported, 4.7% currency-neutral and 5.7% organic • Q2 GAAP and adjusted diluted EPS of $1.85 and $3.17 grew 20.9% and 10.8%, respectively • Year-to-date Cash from Continuing Operations of $1.4 billion and Free Cash Flow of $1.1 billion increased $785 million and over $900 million, respectively • Company raises full-year adjusted EPS guidance and affirms organic revenue growth guidance "Second quarter perfo ...